Business Context and Reporting Period
CalciMedica, Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapeutics for serious illnesses driven by inflammatory processes, primarily targeting calcium release-activated calcium (CRAC) channels. The company's lead product candidate is Auxora (zegocractin), currently in Phase 2 trials for acute pancreatitis and acute kidney injury. This Form 10-Q covers the quarterly period ended September 30, 2024. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.
Key Financial Metrics
| Metric | Q3 2024 | Q3 2023 | 9 Months 2024 | 9 Months 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(5.6) million | $(4.6) million | $(9.4) million | $(30.2) million |
| Operating Expenses | $5.7 million | $4.8 million | $18.0 million | $33.8 million |
| Cash & Equivalents | $9.2 million | $5.5 million (Dec 2023) | $9.2 million (Sep 2024) | $11.6 million (Sep 2023) |
| Short-term Investments | $5.5 million | $5.7 million (Dec 2023) | $5.5 million (Sep 2024) | $5.7 million (Sep 2023) |
| Total Liquidity | $14.6 million | $11.2 million (Dec 2023) | $14.6 million (Sep 2024) | $17.3 million (Sep 2023) |
| Accumulated Deficit | $(155.5) million | $(146.1) million (Dec 2023) | $(155.5) million | $(141.9) million (Sep 2023) |
Note: The company has never generated revenue from product sales. Operating expenses consist primarily of Research and Development (R&D) and General and Administrative (G&A) costs.
Material Changes vs. Prior Period
- Net Loss Reduction: The net loss for the nine months ended September 30, 2024, decreased significantly to $9.4 million compared to $30.2 million in the prior year period. This improvement was driven by a $7.8 million gain from the change in fair value of warrant liabilities and a reduction in operating expenses.
- Operating Expenses: Total operating expenses for the nine months ended September 30, 2024, were $18.0 million, a 47% decrease from $33.8 million in the same period in 2023. The decrease was primarily due to the absence of one-time merger-related charges in 2024, specifically $10.5 million in accelerated stock-based compensation and $5.7 million in severance costs incurred in 2023.
- Capital Structure: In Q1 2024, the company completed a private placement raising approximately $19.0 million in net proceeds. Additionally, a subsequent underwritten public offering closed on November 1, 2024, raising $10.2 million in gross proceeds.
- Warrant Liability: A warrant liability of $3.4 million is recorded on the balance sheet as of September 30, 2024, related to Tranche B Common Warrants issued in the 2024 private placement. This liability did not exist in the same form in the prior year.
Guidance, Outlook, and Risks
- Clinical Progress: The company presented positive data from the CARPO Phase 2b trial in acute pancreatitis, meeting its primary objective. It is currently enrolling patients in the KOURAGE Phase 2 trial for acute kidney injury (AKI) and expects to report results in 2025. The company plans to initiate a Phase 3 program in acute pancreatitis in 2025.
- Liquidity Outlook: Management believes that existing cash, cash equivalents, short-term investments, and proceeds from the November 2024 Follow-On offering will be sufficient to fund operations through the first half of 2026. However, the company explicitly states it will need to raise substantial additional capital to complete development and commercialization of its product candidates.
- ATM Suspension: On October 30, 2024, the company suspended sales under its At-The-Market (ATM) facility until a new prospectus supplement is filed.
- Risk Factors: Key risks include the high uncertainty of clinical trial outcomes, the need for significant additional funding, reliance on third-party manufacturers (including a single-source supplier in China), and the potential for regulatory authorities to not accept data from trials conducted outside the U.S. (specifically the CARPO trial in India).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $14.6 million liquidity position (plus $10.2 million subsequent proceeds) against the projected burn rate to reach the first half of 2026 milestone.
- Warrant Liability Volatility: Monitor the fair value adjustments of the $3.4 million warrant liability, as changes in stock price and volatility can significantly impact reported net income/loss.
- Clinical Trial Enrollment: Track enrollment rates for the KOURAGE (AKI) trial and the timeline for the planned Phase 3 meeting with the FDA regarding acute pancreatitis.
- Regulatory Acceptance of Foreign Data: Assess the FDA's stance on accepting data from the CARPO trial conducted in India, as this is critical for the Phase 3 pathway.
- Supply Chain Dependencies: Review the status of the single-source supplier in China for critical components and any potential impacts from geopolitical tensions or trade restrictions.